Functional Biomaterials in Drug Delivery Applications

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983).

Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 29497

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via G. Colombo, 71, 20133 Milan, Italy
Interests: transdermal dosage forms; orodispersible dosage forms; mucoadhesion; liposomes

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, Università degli Studi di Milano Via G. Colombo, 71 – 20133 Milan, Italy
Interests: parenteral dosage forms; mucoadhesion; biodegradable polymers; freeze drying

Special Issue Information

Dear Colleagues,

Drug delivery systems have been extensively used to optimize the therapeutic performances of both small molecules and biologics by controlling absorption and biodistribution. Functional biomaterials are exploited in the design of prolonged release dosage forms, since their physico-chemical and chemical properties can be appropriately tailored using synthetic or compounding approaches. These new biomaterials can be produced to modulate the drug release rate or to target the active ingredient toward a specific tissue or cell population.

This Special Issue welcomes contributions related to the emerging applications of functional biomaterials in drug delivery. Consideration will be given to novel strategies aiming to rationalize the design of materials and/or drug delivery systems for innovative therapeutic solutions. The research topics may include, but are not limited to, the development of novel biomaterials with unique functional properties, such as mucoadhesion or environmental stimuli-responsiveness; nanocarriers or functional moieties to target the drug release to specific cell types, tissues, or organs; repurposing of known polymers for novel engineered structures. These aspects will be also discussed in the light of emerging technologies that allow to broaden the field of applications.

This Special Issue is seeking contributions from researchers to update the state-of-the-art and to disseminate the latest progress in the application of functionalized biomaterials to drug delivery. We encourage authors to submit research papers and comprehensive reviews on this topic.

Prof. Francesco Cilurzo
Prof. Francesca Selmin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Drug delivery systems
  • Functionalization
  • Biopolymers
  • Nanoparticles
  • Nanocomposites
  • Surface decoration
  • Controlled release
  • Drug targeting
  • biodistribution

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2724 KiB  
Article
Controlled Release of 5-FU from Chi–DHA Nanoparticles Synthetized with Ionic Gelation Technique: Evaluation of Release Profile Kinetics and Cytotoxicity Effect
by Mariarosa Ruffo, Ortensia Ilaria Parisi, Francesco Patitucci, Marco Dattilo, Rocco Malivindi, Fabio Amone, Catia Morelli, Alessandra Nigro, Diego Sisci and Francesco Puoci
J. Funct. Biomater. 2020, 11(3), 48; https://doi.org/10.3390/jfb11030048 - 8 Jul 2020
Cited by 4 | Viewed by 3117
Abstract
The ionic gelation technique allows us to obtain nanoparticles able to function as carriers for hydrophobic anticancer drugs, such as 5-fluoruracil (5-FU). In this study, reticulated chitosan– docosahexaenoic acid (Chi–DHAr) nanoparticles were synthesized by using a chemical reaction between amine groups of chitosan [...] Read more.
The ionic gelation technique allows us to obtain nanoparticles able to function as carriers for hydrophobic anticancer drugs, such as 5-fluoruracil (5-FU). In this study, reticulated chitosan– docosahexaenoic acid (Chi–DHAr) nanoparticles were synthesized by using a chemical reaction between amine groups of chitosan (Chi) and carboxylic acids of docosahexaenoic acid (DHA) and the presence of a link between Chi and DHA was confirmed by FT-IR, while the size and morphology of the obtained Chi-DHAr nanoparticles was evaluated with dynamic light scattering (DLS) and scanning electron microscopy (SEM), respectively. Drug-loading content (DLC) and drug-loading efficiency (DLE) of 5-FU in Chi-DHAr nanoparticles were 33.74 ± 0.19% and 7.9 ± 0.26%, respectively, while in the non-functionalized nanoparticles (Chir + 5FU), DLC, and DLE were in the ranges of 23.73 ± 0.14%, 5.62%, and 0.23%, respectively. The in vitro release profile, performed in phosphate buffer saline (PBS, pH 7.4) at 37 °C, indicated that the synthetized Chi–DHAr nanoparticles provided a sustained release of 5-FU. Based on the obtained regression coefficient value (R2), the first order kinetic model provided the best fit for both Chir and Chi-DHAr nanoparticles. Finally, cytotoxicity studies of chitosan, 5-FU, Chir, Chir + 5-FU, Chi-DHAr, and Chi-DHAr + 5-FU nanoparticles were conducted. Overall, Chi-DHAr nanoparticles proved to be much more biocompatible than Chir nanoparticles while retaining the ability to release the drug with high efficiency, especially towards specific types of cancerous cells. Full article
(This article belongs to the Special Issue Functional Biomaterials in Drug Delivery Applications)
Show Figures

Graphical abstract

15 pages, 5843 KiB  
Article
Silk-Based Therapeutics Targeting Pseudomonas aeruginosa
by Tina B. McKay, Rachael N. Parker, Morgan J. Hawker, Meghan McGill and David L. Kaplan
J. Funct. Biomater. 2019, 10(3), 41; https://doi.org/10.3390/jfb10030041 - 13 Sep 2019
Cited by 1 | Viewed by 5439
Abstract
Pseudomonas aeruginosa (P. aeruginosa) infections may lead to severe damage of the cornea, mucosa, and skin. The highly aggressive nature of P. aeruginosa and the rise in multi-drug resistance, particularly in nosocomial settings, lead to an increased risk for permanent tissue [...] Read more.
Pseudomonas aeruginosa (P. aeruginosa) infections may lead to severe damage of the cornea, mucosa, and skin. The highly aggressive nature of P. aeruginosa and the rise in multi-drug resistance, particularly in nosocomial settings, lead to an increased risk for permanent tissue damage and potentially death. Thus, a growing need exists to develop alternative treatments to reduce both the occurrence of bacterial infection and biofilm development, as well as pathological progression post-infection. Silk derived from Bombyx mori silkworms serves as a unique biomaterial that is biocompatible with low immunogenicity and high versatility, and thereby ideal for stabilizing therapeutics. In this study, we assessed the cytotoxicity of P. aeruginosa on human corneal stromal stem cells and two mucosal cell lines (Caco-2 and HT29-MTX). To determine whether antibiotic-immobilized scaffolds can serve as alternative therapeutics to free, diffuse forms, we developed novel gentamicin-conjugated silk films as functional scaffolds and compared antimicrobial effects and free gentamicin. The advantages of generating a surface coating with a covalently-bound antibiotic may reduce potential side-effects associated with free gentamicin, as well as limit the diffusion of the drug. Our results suggest that gentamicin conjugated to native silk and carboxyl-enriched silk inhibits P. aeruginosa growth. Development of stabilized antibiotic treatments with surface toxicity selective against bacteria may serve as an alternative approach to treat active infections, as well as potential prophylactic use as coatings in high-risk cases, such as post-surgical complications or prolonged hospitalization. Full article
(This article belongs to the Special Issue Functional Biomaterials in Drug Delivery Applications)
Show Figures

Figure 1

14 pages, 1429 KiB  
Communication
Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT
by Marcus Hill, Richard N. Cunningham, Rania M. Hathout, Christopher Johnston, John G. Hardy and Marie E. Migaud
J. Funct. Biomater. 2019, 10(2), 26; https://doi.org/10.3390/jfb10020026 - 13 Jun 2019
Cited by 46 | Viewed by 9368
Abstract
Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) [...] Read more.
Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) requires sufficient levels of therapeutic drug to maintain a drug concentration above the microbial inhibitory concentration (MIC) of the bacteria. Previous studies have shown that loading of aminoglycoside drugs in poly(lactic-co-glycolic) acid (PLGA)-based delivery systems is generally poor due to weak interactions between the drug and the polymer. The formation of complexes of tobramycin with dioctylsulfosuccinate (AOT) allows the effective loading of the drug in PLGA-nanoparticles and such nanoparticles can effectively deliver the antimicrobial aminoglycoside with retention of tobramycin antibacterial function. Full article
(This article belongs to the Special Issue Functional Biomaterials in Drug Delivery Applications)
Show Figures

Graphical abstract

13 pages, 10442 KiB  
Article
3D Printing Custom Bioactive and Absorbable Surgical Screws, Pins, and Bone Plates for Localized Drug Delivery
by Karthik Tappa, Udayabhanu Jammalamadaka, Jeffery A. Weisman, David H. Ballard, Dallas D. Wolford, Cecilia Pascual-Garrido, Larry M. Wolford, Pamela K. Woodard and David K. Mills
J. Funct. Biomater. 2019, 10(2), 17; https://doi.org/10.3390/jfb10020017 - 1 Apr 2019
Cited by 61 | Viewed by 10975
Abstract
Additive manufacturing has great potential for personalized medicine in osseous fixation surgery, including maxillofacial and orthopedic applications. The purpose of this study was to demonstrate 3D printing methods for the fabrication of patient-specific fixation implants that allow for localized drug delivery. 3D printing [...] Read more.
Additive manufacturing has great potential for personalized medicine in osseous fixation surgery, including maxillofacial and orthopedic applications. The purpose of this study was to demonstrate 3D printing methods for the fabrication of patient-specific fixation implants that allow for localized drug delivery. 3D printing was used to fabricate gentamicin (GS) and methotrexate (MTX)-loaded fixation devices, including screws, pins, and bone plates. Scaffolds with different infill ratios of polylactic acid (PLA), both without drugs and impregnated with GS and MTX, were printed into cylindrical and rectangular-shaped constructs for compressive and flexural strength mechanical testing, respectively. Bland PLA constructs showed significantly higher flexural strength when printed in a Y axis at 100% infill compared to other axes and infill ratios; however, there was no significant difference in flexural strength between other axes and infill ratios. GS and MTX-impregnated constructs had significantly lower flexural and compressive strength as compared to the bland PLA constructs. GS-impregnated implants demonstrated bacterial inhibition in plate cultures. Similarly, MTX-impregnated implants demonstrated a cytotoxic effect in osteosarcoma assays. This proof of concept work shows the potential of developing 3D printed screws and plating materials with the requisite mechanical properties and orientations. Drug-impregnated implants were technically successful and had an anti-bacterial and chemotherapeutic effect, but drug addition significantly decreased the flexural and compressive strengths of the custom implants. Full article
(This article belongs to the Special Issue Functional Biomaterials in Drug Delivery Applications)
Show Figures

Figure 1

Back to TopTop